Monitoring the Course of MS With Optical Coherence Tomography

Alexander U. Brandt, Elena H. Martinez-Lapiscina, Rachel Nolan, Shiv Saidha

Research output: Contribution to journalReview article

Abstract

Retinae of patients with multiple sclerosis (MS), as part of the central nervous system (CNS), display inflammatory and neurodegenerative changes. There is increasing evidence suggesting that retinal changes, and in particular neurodegeneration, mirror global CNS alterations in MS. Spectral domain optical coherence tomography (SD-OCT) is an inexpensive, rapid, non-invasive, and reproducible imaging technique that generates high-resolution images of tissues such as the retina. An advantage of SD-OCT over magnetic resonance imaging techniques in the assessment of neurodegeneration may be its sensitivity to capture changes at the individual patient level. Several studies demonstrate that changes within the inner retina (primarily as a reflection of optic neuropathy), as assessed by OCT, correlate with reduced quality of life, visual dysfunction, and global disability in MS. Moreover, longitudinal studies suggest that inner retinal thinning is an early phenomenon in MS and that retinal thinning may occur independent of previous symptomatic episodes of optic neuritis, significantly correlating with inflammatory disease. Preliminary studies suggest that MS disease-modifying therapies may have differential effects on OCT-determined rates of retinal atrophy, supporting a potential utility for OCT to investigate the neuroprotective benefits of disease-modifying therapies in MS, as well as an outcome in trials of putatively neuroprotective strategies.

Original languageEnglish (US)
Article number15
JournalCurrent Treatment Options in Neurology
Volume19
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Optical Coherence Tomography
Multiple Sclerosis
Retina
Central Nervous System
Optic Neuritis
Optic Nerve Diseases
Atrophy
Longitudinal Studies
Quality of Life
Magnetic Resonance Imaging
Therapeutics

Keywords

  • Monitoring
  • Multiple sclerosis
  • Retina
  • Spectral domain optical coherence tomography
  • Therapy response

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Monitoring the Course of MS With Optical Coherence Tomography. / Brandt, Alexander U.; Martinez-Lapiscina, Elena H.; Nolan, Rachel; Saidha, Shiv.

In: Current Treatment Options in Neurology, Vol. 19, No. 4, 15, 01.04.2017.

Research output: Contribution to journalReview article

Brandt, Alexander U. ; Martinez-Lapiscina, Elena H. ; Nolan, Rachel ; Saidha, Shiv. / Monitoring the Course of MS With Optical Coherence Tomography. In: Current Treatment Options in Neurology. 2017 ; Vol. 19, No. 4.
@article{70f5c033fb374707b0deb3d6c348a45a,
title = "Monitoring the Course of MS With Optical Coherence Tomography",
abstract = "Retinae of patients with multiple sclerosis (MS), as part of the central nervous system (CNS), display inflammatory and neurodegenerative changes. There is increasing evidence suggesting that retinal changes, and in particular neurodegeneration, mirror global CNS alterations in MS. Spectral domain optical coherence tomography (SD-OCT) is an inexpensive, rapid, non-invasive, and reproducible imaging technique that generates high-resolution images of tissues such as the retina. An advantage of SD-OCT over magnetic resonance imaging techniques in the assessment of neurodegeneration may be its sensitivity to capture changes at the individual patient level. Several studies demonstrate that changes within the inner retina (primarily as a reflection of optic neuropathy), as assessed by OCT, correlate with reduced quality of life, visual dysfunction, and global disability in MS. Moreover, longitudinal studies suggest that inner retinal thinning is an early phenomenon in MS and that retinal thinning may occur independent of previous symptomatic episodes of optic neuritis, significantly correlating with inflammatory disease. Preliminary studies suggest that MS disease-modifying therapies may have differential effects on OCT-determined rates of retinal atrophy, supporting a potential utility for OCT to investigate the neuroprotective benefits of disease-modifying therapies in MS, as well as an outcome in trials of putatively neuroprotective strategies.",
keywords = "Monitoring, Multiple sclerosis, Retina, Spectral domain optical coherence tomography, Therapy response",
author = "Brandt, {Alexander U.} and Martinez-Lapiscina, {Elena H.} and Rachel Nolan and Shiv Saidha",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s11940-017-0452-7",
language = "English (US)",
volume = "19",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Monitoring the Course of MS With Optical Coherence Tomography

AU - Brandt, Alexander U.

AU - Martinez-Lapiscina, Elena H.

AU - Nolan, Rachel

AU - Saidha, Shiv

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Retinae of patients with multiple sclerosis (MS), as part of the central nervous system (CNS), display inflammatory and neurodegenerative changes. There is increasing evidence suggesting that retinal changes, and in particular neurodegeneration, mirror global CNS alterations in MS. Spectral domain optical coherence tomography (SD-OCT) is an inexpensive, rapid, non-invasive, and reproducible imaging technique that generates high-resolution images of tissues such as the retina. An advantage of SD-OCT over magnetic resonance imaging techniques in the assessment of neurodegeneration may be its sensitivity to capture changes at the individual patient level. Several studies demonstrate that changes within the inner retina (primarily as a reflection of optic neuropathy), as assessed by OCT, correlate with reduced quality of life, visual dysfunction, and global disability in MS. Moreover, longitudinal studies suggest that inner retinal thinning is an early phenomenon in MS and that retinal thinning may occur independent of previous symptomatic episodes of optic neuritis, significantly correlating with inflammatory disease. Preliminary studies suggest that MS disease-modifying therapies may have differential effects on OCT-determined rates of retinal atrophy, supporting a potential utility for OCT to investigate the neuroprotective benefits of disease-modifying therapies in MS, as well as an outcome in trials of putatively neuroprotective strategies.

AB - Retinae of patients with multiple sclerosis (MS), as part of the central nervous system (CNS), display inflammatory and neurodegenerative changes. There is increasing evidence suggesting that retinal changes, and in particular neurodegeneration, mirror global CNS alterations in MS. Spectral domain optical coherence tomography (SD-OCT) is an inexpensive, rapid, non-invasive, and reproducible imaging technique that generates high-resolution images of tissues such as the retina. An advantage of SD-OCT over magnetic resonance imaging techniques in the assessment of neurodegeneration may be its sensitivity to capture changes at the individual patient level. Several studies demonstrate that changes within the inner retina (primarily as a reflection of optic neuropathy), as assessed by OCT, correlate with reduced quality of life, visual dysfunction, and global disability in MS. Moreover, longitudinal studies suggest that inner retinal thinning is an early phenomenon in MS and that retinal thinning may occur independent of previous symptomatic episodes of optic neuritis, significantly correlating with inflammatory disease. Preliminary studies suggest that MS disease-modifying therapies may have differential effects on OCT-determined rates of retinal atrophy, supporting a potential utility for OCT to investigate the neuroprotective benefits of disease-modifying therapies in MS, as well as an outcome in trials of putatively neuroprotective strategies.

KW - Monitoring

KW - Multiple sclerosis

KW - Retina

KW - Spectral domain optical coherence tomography

KW - Therapy response

UR - http://www.scopus.com/inward/record.url?scp=85016934418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016934418&partnerID=8YFLogxK

U2 - 10.1007/s11940-017-0452-7

DO - 10.1007/s11940-017-0452-7

M3 - Review article

VL - 19

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 4

M1 - 15

ER -